Stock · ALKEM · Healthcare
ALKEM share price target 2026
Support, resistance, the F&O structure and the BazaarBaazi Crack Score for ALKEM LABORATORIES LIMITED, refreshed every end-of-day run. A systematic, data-only read on ALKEM LABORATORIES LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
The verdict
BazaarBaazi reads ALKEM as constructive with a Crack Score of 83/100 as of 25 Jul 2026.
BazaarBaaziSource & method
The scanner's readScanned · scanned 24 Jul 2026
Where ALKEM stands on the 500-name BazaarBaazi setup scanner: technicals, filed fundamentals and money flow read together, refreshed every run.
Scanned and scored this run, but the evidence is incomplete or conflicted. The engine fails closed to NO_TRADE.
Technical axis
100/100Fundamental axis
33/100Money flow
68/100Result pulse · Q4 FY26
40/100Technical evidence
price above 50DMA
price above 150DMA
price above 200DMA
50 > 150 > 200 DMA (clean stack)
uptrend frame (50 > 200 DMA)
50DMA rising
pulled back to a rising MA
RSI 53.2 (cooled, not broken)
Red flags
above 200DMA (not a confirmed short-side trend)
Relative valuation
P/E (TTM)
29.1P/E vs sector
+0.6%Sector percentile
13PEG
n/aScanner levels from the deterministic engine run of 2026-07-24, not a SEBI-registered recommendation and not investment advice. The fundamental axis reads the official filing: Q4 FY26 result.
Price target: support and resistanceComputed 25 Jul 2026
Support and resistance for ALKEM are read inside the latest show; no spot was printed in the most recent editorial note.
Levels are read inside the latest show. The most recent editorial reference is Systematic Read on 21 Jul 2026.
These are structural reference lines, not a SEBI-registered price target. BazaarBaazi is independent media; the levels frame how the desk reads the ALKEM chart, refreshed every end-of-day run.
The Crack Score, and how it is built83 / 100 · High conviction
The Crack Score is a deterministic 0 to 100 conviction number. Here is exactly what moved it for ALKEM, so the figure is a transparent signal rather than a vibe.
Base 50, adjusted by the factors above and clamped to 0 to 100. How the Crack Score works.
The F&O viewHorizon · swing
How the futures and options structure on ALKEM reads right now.
The editorial price read on ALKEM is bullish. Strike-level option inventory is unavailable, so the page withholds writer, wall and pin claims. Single-stock F&O on ALKEM can be thinner than index F&O, so the desk weights price and filed evidence over raw OI. This is not a derivatives trade recommendation.
Why it movedLatest editorial line
The most recent BazaarBaazi read on what is driving ALKEM.
Systematic read: a disclosed, data-only model on real 1-year price structure.
Read in Systematic Read on 21 Jul 2026. Why ALKEM moved, the living explainer, tracks every move on one URL.
Latest filed resultsQ4 FY26
ALKEM LABORATORIES LIMITED's most recent quarter, parsed straight from the official NSE filing. Every figure links back to its primary source.
Result Pulse
40 / 100Revenue
Rs 3,603 crNet profit
Rs 251 crEPS (quarter)
Rs 19.77| Growth | YoY | QoQ |
|---|---|---|
| Revenue | +14.6% | -3.6% |
| Net profit | -22.1% | -61.5% |
| Net margin | +7.0% | |
Figures are the Q4 FY26 result for ALKEM LABORATORIES LIMITED, parsed straight from the official NSE integrated filing and verified to the paisa. The EPS shown is for the quarter, not a trailing-twelve-month figure, so it is not a P/E input.
Earnings history, every filed quarter32 quarters on record
ALKEM LABORATORIES LIMITED's official quarterly revenue, EPS and Result Pulse trail, every quarter the desk holds from the verified filings export, back to 30 Jun 2018. These are quarterly facts, not TTM valuation inputs.
ALKEM official result trail
32 quarters
Quarterly figures only: revenue, net profit and EPS are copied from official filings. EPS here is not trailing twelve month EPS and is not used for valuation.
| Quarter | Revenue | EPS | PAT YoY | Pulse | Source |
|---|---|---|---|---|---|
| Q4 FY26ended 31 Mar 2026 / Consolidated, audited | Rs 3,603 cr | Rs 19.77 | n/a | n/a | Filing |
| Q3 FY26ended 31 Dec 2025 / Consolidated, audited | Rs 3,737 cr | Rs 53.19 | n/a | 52/100 | Filing |
| Q2 FY26ended 30 Sep 2025 / Consolidated, audited | Rs 4,001 cr | Rs 63.99 | n/a | 64/100 | Filing |
| Q1 FY26ended 30 Jun 2025 / Consolidated, audited | Rs 3,371 cr | Rs 55.56 | n/a | 58/100 | Filing |
| Q4 FY25ended 31 Mar 2025 / Consolidated, audited | Rs 3,144 cr | Rs 25.57 | n/a | 50/100 | Filing |
| Q3 FY25ended 31 Dec 2024 / Consolidated, audited | Rs 3,374 cr | Rs 52.34 | n/a | n/a | Filing |
| Q2 FY25ended 30 Sep 2024 / Consolidated, audited | Rs 3,415 cr | Rs 57.60 | n/a | n/a | Filing |
| Q1 FY25ended 30 Jun 2024 / Consolidated, audited | Rs 3,032 cr | Rs 45.60 | n/a | n/a | Filing |
| Q4 FY24ended 31 Mar 2024 / Consolidated, audited | Rs 2,936 cr | Rs 24.55 | n/a | n/a | Filing |
| Q3 FY24ended 31 Dec 2023 / Consolidated, audited | Rs 3,324 cr | Rs 49.76 | n/a | n/a | Filing |
| Q2 FY24ended 30 Sep 2023 / Consolidated, audited | Rs 3,440 cr | Rs 51.90 | n/a | n/a | Filing |
| Q1 FY24ended 30 Jun 2023 / Consolidated, audited | Rs 2,968 cr | Rs 23.98 | n/a | n/a | Filing |
| Q4 FY23ended 31 Mar 2023 / Consolidated, audited | Rs 2,903 cr | Rs 5.94 | n/a | n/a | Filing |
| Q3 FY23ended 31 Dec 2022 / Consolidated, audited | Rs 3,041 cr | Rs 38.03 | n/a | n/a | Filing |
| Q2 FY23ended 30 Sep 2022 / Consolidated, audited | Rs 3,079 cr | Rs 27.67 | n/a | n/a | Filing |
| Q1 FY23ended 30 Jun 2022 / Consolidated, audited | Rs 2,576 cr | Rs 10.68 | n/a | n/a | Filing |
| Q4 FY22ended 31 Mar 2022 / Consolidated, audited | Rs 2,484 cr | Rs 9.00 | n/a | n/a | Filing |
| Q3 FY22ended 31 Dec 2021 / Consolidated, audited | Rs 2,619 cr | Rs 43.96 | n/a | n/a | Filing |
| Q2 FY22ended 30 Sep 2021 / Consolidated, audited | Rs 2,800 cr | Rs 45.52 | n/a | n/a | Filing |
| Q1 FY22ended 30 Jun 2021 / Consolidated, audited | Rs 2,731 cr | Rs 39.15 | n/a | n/a | Filing |
| Q4 FY21ended 31 Mar 2021 / Consolidated, audited | Rs 2,192 cr | Rs 20.07 | n/a | n/a | Filing |
| Q3 FY21ended 31 Dec 2020 / Consolidated, audited | Rs 2,318 cr | Rs 37.72 | n/a | n/a | Filing |
| Q2 FY21ended 30 Sep 2020 / Consolidated, audited | Rs 2,363 cr | Rs 39.48 | n/a | n/a | Filing |
| Q1 FY21ended 30 Jun 2020 / Consolidated, audited | Rs 2,003 cr | Rs 35.30 | n/a | n/a | Filing |
| Q4 FY20ended 31 Mar 2020 / Consolidated, audited | Rs 2,049 cr | Rs 15.79 | n/a | n/a | Filing |
| Q3 FY20ended 31 Dec 2019 / Consolidated, audited | Rs 2,182 cr | Rs 31.95 | n/a | n/a | Filing |
| Q2 FY20ended 30 Sep 2019 / Consolidated, audited | Rs 2,264 cr | Rs 31.02 | n/a | n/a | Filing |
| Q1 FY20ended 30 Jun 2019 / Consolidated, audited | Rs 1,850 cr | Rs 15.51 | n/a | n/a | Filing |
| Q4 FY19ended 31 Mar 2019 / Consolidated, audited | Rs 1,854 cr | Rs 14.00 | n/a | n/a | Filing |
| Q3 FY19ended 31 Dec 2018 / Consolidated, audited | Rs 1,925 cr | Rs 16.94 | n/a | n/a | Filing |
| Q2 FY19ended 30 Sep 2018 / Consolidated, audited | Rs 1,919 cr | Rs 21.28 | n/a | n/a | Filing |
| Q1 FY19ended 30 Jun 2018 / Consolidated, audited | Rs 1,669 cr | Rs 11.39 | n/a | n/a | Filing |
The official financialsFiled to 31 Mar 2026
ALKEM LABORATORIES LIMITED's statements as filed: trailing twelve month P&L, the balance sheet, and the cash engine. Parsed from official XBRL, shown in crore.
Trailing twelve months, on filed quarters
Revenue (TTM)
14,712 crNet profit (TTM)
2,351 crEBIT (TTM)
3,032 crProfit before tax (TTM)
2,871 crNet margin (TTM)
16.0%Finance costs (TTM)
161 crBalance sheet, as filed 2026-03-31
Total assets
20,873 crShareholder equity
14,349 crTotal borrowings
1,624 crCash and equivalents
248 crInventory
3,333 crTrade receivables
2,979 crThe cash engine, latest filed year
Operating cash flow
1,963 crCapex
617 crFree cash flow
1,346 crInvesting flow
-1,667 crFinancing flow
-503 crAnnual trail, filed year over filed year
| Year | Revenue | Net profit | Equity | Borrowings | CFO |
|---|---|---|---|---|---|
| FY26 | 14,712 cr | 2,351 cr | 14,349 cr | 1,624 cr | 1,963 cr |
| FY25 | 12,965 cr | 2,215 cr | 12,434 cr | 1,063 cr | 1,913 cr |
| FY24 | 12,668 cr | 1,811 cr | 10,714 cr | 1,214 cr | 1,948 cr |
| FY23 | 11,599 cr | 1,007 cr | 9,435 cr | 1,397 cr | 1,683 cr |
| FY22 | 10,634 cr | 1,680 cr | 8,847 cr | 2,668 cr | 1,111 cr |
| FY21 | 8,865 cr | 1,618 cr | 7,558 cr | 1,670 cr | n/a |
Every figure is parsed from ALKEM LABORATORIES LIMITED's official NSE XBRL filings by the BazaarBaazi earnings lab and shown in crore rupees. Display data, not a valuation model input.
Management on record32 earnings calls
Every ALKEM earnings call BazaarBaazi has indexed, latest 30 Jun 2026. Read management in its own words, straight from the filed transcript.
ALKEM LABORATORIES LIMITED earnings calls on record
32 calls since 31 Jul 2018
Show 24 older calls
Each entry links to the transcript PDF the company filed with the exchange. Primary sources, in management's own words.
What changed2 disclosures
Every recent official filing from ALKEM LABORATORIES LIMITED, straight from the exchange feed, with the BazaarBaazi Event Heat on the disclosure flow.
ALKEM LABORATORIES LIMITED has filed 2 official disclosures recently. The most recent is a Earnings dated 31 Mar 2026.
Event Heat
67 / 100Event Heat is a dated net read of ALKEM LABORATORIES LIMITED's last 180 days of official disclosures, balancing the constructive filings against the ones to watch. It is a signal from what the company has filed, not investment advice. Every line above links to its official exchange filing, and the full market desk is at the disclosures hub.
Key fundamentalsEditorial reference
The anchor data BazaarBaazi references when reading the ALKEM chart. Not a substitute for a registered research note.
| Ticker | ALKEM |
|---|---|
| Full name | ALKEM LABORATORIES LIMITED |
| Sector | Healthcare |
| Index class | MID CAP |
| ISIN | INE540L01014 |
| Market-cap band | ~72,164 cr (indicative) |
| Last referenced level | Inside latest show |
| Last session move | Not referenced this cycle |
| Editorial line in | Systematic Read on 21 Jul 2026 |
| Aliases tracked | ALKEM |
Reference chartLevels in show
The daily frame the desk reads on ALKEM.
FAQ11 reader questions · AEO-eligible
The line on ALKEM, distilled and schema-marked for AI Overview, Perplexity, and reader search.
What is the ALKEM share price target for 2026?
BazaarBaazi does not publish a SEBI-registered price target on ALKEM. The desk reads structural support and resistance inside each show against the printed spot; the most recent editorial line is Systematic Read on 21 Jul 2026.
What is BazaarBaazi's Crack Score for ALKEM?
The BazaarBaazi Crack Score for ALKEM is 83 out of 100 as of 25 Jul 2026, a high conviction reading. It is a computed conviction number from the signed stance, how consistent the recent verdicts have been, the quality of the printed structure, and how fresh the review is. It is a transparency signal, not investment advice.
What is the F&O view on ALKEM?
Strike-level option inventory for ALKEM is unavailable, so BazaarBaazi withholds participant, direction and positioning claims. The editorial chart stance is not substituted for an option-chain observation.
What sector is ALKEM in and which peers does BazaarBaazi track?
ALKEM sits in Healthcare (mid cap), indicative market cap ~72,164 cr (indicative), ISIN INE540L01014. The peers BazaarBaazi reads alongside it are GLAND PHARMA LIMITED, Eris Lifesciences Limited, ACUTAAS CHEMICALS LIMITED. A systematic, data-only read on ALKEM LABORATORIES LIMITED: where it trades versus its 50-day and 200-day lines, the live 52-week range, and momentum, refreshed from the scanner's real price series each run.
How often is the ALKEM view updated?
This page is one evergreen URL refreshed in place. The Crack Score and levels re-compute on every BazaarBaazi end-of-day run, and the dated stamp shows the last refresh. The latest signed verdict on ALKEM is bullish, published in Systematic Read on 21 Jul 2026.
Is ALKEM a qualifying setup on the BazaarBaazi scanner right now?
On the 2026-07-24 run of the 500-name BazaarBaazi setup scanner, ALKEM LABORATORIES LIMITED sits in the Scanned tier with a setup score of 73/100 (technical 100, fundamental 33). The scanner is a deterministic engine over real OHLCV and official filings, refreshed nightly, and it is a signal rather than investment advice.
Where can I read ALKEM LABORATORIES LIMITED's earnings call transcripts?
BazaarBaazi indexes 32 ALKEM earnings calls going back to 2018-07-31, latest 2026-06-30. Every entry on this page links straight to the transcript PDF the company filed with the exchange, so you read management in the primary source.
What was ALKEM LABORATORIES LIMITED's Q4 FY26 net profit?
ALKEM LABORATORIES LIMITED reported a net profit of Rs 251 cr for Q4 FY26 (the quarter ended 31 March 2026). That is -22.1% year on year. The figure is from the company's official NSE filing.
What was ALKEM LABORATORIES LIMITED's Q4 FY26 revenue?
ALKEM LABORATORIES LIMITED reported revenue of Rs 3,603 cr for Q4 FY26. That is +14.6% year on year. The figure is from the company's official NSE filing.
How does BazaarBaazi rate ALKEM LABORATORIES LIMITED's Q4 FY26 result?
BazaarBaazi gives ALKEM LABORATORIES LIMITED's Q4 FY26 result a Result Pulse of 40 out of 100, with a verdict of Mixed. The Result Pulse is a BazaarBaazi editorial score for the quality of the filed result, not investment advice.
What has Alkem Laboratories Ltd announced recently?
The most recent official filing on record for Alkem Laboratories Ltd is an earnings dated 31 Mar 2026. It is the company's own earnings disclosure to the exchange, and it links to that filing on the BazaarBaazi stock page rather than to any third-party summary.
Related stock views
The names BazaarBaazi reads alongside ALKEM, each a living view refreshed every end-of-day run.